Welcome Guest

Abstract
Add to Favorites
  • Volume 5
  •  Issue 5
  • Publication Date: June 2007


A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer


Amy M. Lin, Brian I. Rini, Mika K. Derynck, Vivian Weinberg, Margaret Park, Charles J. Ryan, Jonathan E. Rosenberg, Glenn Bubley, Eric J. Small

Background: Docetaxel/estramustine was a commonly used regimen to treat metastatic hormone-refractory prostate cancer. Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models. Patients and Methods: A phase I trial of docetaxel/estramustine/imatinib was undertaken to determine the safety and maximum tolerated dose of this combination. Patients with progressive, metastatic, hormone-refractory prostate cancer were treated every 21 days with fixed doses of estramustine (280 mg orally 3 times a day on days 1-5), imatinib (400 mg orally daily on days 1-21), dexamethasone (8 mg orally twice daily on days 1-3), and prophylactic warfarin (2 mg orally daily on days 1-21). Cohorts of 3-6 patients were enrolled to receive escalating doses of docetaxel on day 2 from 50 mg/m2 to 60 mg/m2 to 70 mg/m2. Thirteen patients were treated. Results: On dose level 3 (docetaxel 70 mg/m2 and imatinib 400 mg daily), 2 patients experienced grade 3 elevations in prothrombin time, attributed to the interaction between imatinib and warfarin. The protocol was amended to include an intermediate dose level (docetaxel 60 mg/m2 and imatinib 300 mg daily). However, in the overall study, there were 5 unacceptable toxicities (2 cerebrovascular accidents, 1 myocardial infarction, 1 mesenteric ischemia, and 1 deep venous thrombosis) in 13 patients; 2 of those toxicities resulted in death. The study was closed early to further accrual. Conclusion: The high incidence of thromboembolic events observed when imatinib was combined with docetaxel/estramustine precludes further exploration of this regimen.

Key words: Dose-limiting toxicities, Platelet-derived growth factor receptor, Prostate-specific antigen



  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  16. pintarbersamamedan.org
  17. https://pintarbersamamanado.org
  18. https://pintarbersamasorong.org/dana
  19. DATA HK
  20. HK LOTTO
  21. PENGELUARAN HK
  22. DATA HK
  23. TOGEL HK
  24. PENGELUARAN SGP
  25. TOGEL SDY
  26. TOGEL HONGKONG
  27. PENGELUARAN SGP
  28. LIVE DRAW SDY
  1. KELUARAN SGP
  2. TOGEL